D. Isla

发表

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

E. Felip, F. de Marinis, G. Altavilla, 2012, The Lancet. Oncology.

Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer.

J. Padilla, E. Felip, R. Rosell, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Influence of Lung Microbiota on Lung Carcinogenesis, Immunity, and Immunotherapy.

D. Isla, Á. Artal, A. Rezusta, 2020, Trends in cancer.

A variant associated with nicotine dependence, lung cancer and peripheral arterial disease

Daniel F. Gudbjartsson, Kari Stefansson, Gudmar Thorleifsson, 2008, Nature.

Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium.

Paul Brennan, Yun-Chul Hong, Kari Stefansson, 2010, Journal of the National Cancer Institute.

Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non-small cell lung cancer: comparison of two Phase II trials.

E. Felip, R. Rosell, C. Camps, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Lung cancer and treatment in elderly patients: the Achilles Study.

R. Rosell, N. Viñolas, M. Provencio, 2009, Lung cancer.

Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.

D. Gandara, E. Felip, L. Paz-Ares, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SEOM guidelines on thrombosis in cancer patients

N. Viñolas, D. Isla, A. Muñoz, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

C. García-Girón, J. Bosch-Barrera, E. Esteban, 2021, BMC cancer.

Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.

M. Taron, M. Santarpia, M. Sánchez-Ronco, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment

J. Lambea, R. Hitt, D. Isla, 2010, British Journal of Cancer.

SEOM guidelines for the treatment of malignant pleural mesothelioma

I. Bover, D. Isla, J. Remon, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Adjuvant docetaxel for high-risk, node-negative breast cancer.

A. Ruíz, A. Lluch, J. Zaluski, 2010, The New England journal of medicine.

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.

A. Lluch, J. Zaluski, M. Martín, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

F. López-Ríos, E. Felip, L. Paz-Ares, 2019, Clinical and Translational Oncology.

Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy

D. Isla, J. Pardo, A. Ramírez-Labrada, 2020, Frontiers in Oncology.

Early intervention with epoetin beta prevents severe anaemia in lung cancer patients receiving platinum-based chemotherapy: a subgroup analysis of the NeoPrevent study.

M. Dómine, J. De Castro, D. Isla, 2008, Lung cancer.

Phase II study of capecitabine as palliative treatment for patients (p) with squamous head and neck cancer (HNC) with locoregional and/or metastatic relapse after previous platinum-based treatment (PBT): Final results of Spanish Head and Neck Cancer Group (TTCC).

J. Lambea, R. Hitt, D. Isla, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation

V. Guillem, L. Paz-Ares, R. Rosell, 2010, European Respiratory Journal.

SEOM Clinical Guideline for bone metastases from solid tumours (2016)

M. Martín, M. A. Seguí, C. Grávalos, 2016, Clinical and Translational Oncology.

Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression

R. Rosell, M. Taron, N. Reguart, 2009, PloS one.

Comparation of different malnutrition screening tools according to GLIM criteria in cancer outpatients

J. Lambea, J. Arbonés-Mainar, D. Isla, 2021, European Journal of Clinical Nutrition.

SEOM clinical guidelines for the treatment of thyroid cancer

D. Isla, J. Cruz, J. Martínez Trufero, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Functions and workload of medical oncologists in Spain

J. Albanell, E. Alba, Á. Rodríguez-Lescure, 2012, Clinical and Translational Oncology.

Pilot study on workload estimate in breast cancer, lung cancer and colorectal cancer in a Medical Oncology Service at Valme hospital

J. Albanell, E. Alba, Á. Rodríguez-Lescure, 2012, Clinical and Translational Oncology.

In answer to: “Comments to SEOM clinical guidelines for the treatment of thyroid cancer” by Garcilaso Riesco-Eizaguirre et al

J. Capdevila, D. Isla, J. Cruz, 2012, Clinical and Translational Oncology.

Randomized phase III trial of customized adjuvant chemotherapy (CT) according BRCA-1 expression levels in patients with node positive resected non-small cell lung cancer (NSCLS) SCAT: A Spanish Lung Cancer Group trial (Eudract:2007-000067-15; NCTgov: 00478699).

R. Rosell, B. Massuti, J. Sánchez-Payá, 2015 .

Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel

D. Isla, M. Brosa, H. Finnern, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy

L. Paz-Ares, C. Rolfo, B. Massuti, 2017, Clinical and Translational Oncology.

SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours (GEP NETS)

R. Salazar, R. García-Carbonero, D. Isla, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)

M. Provencio, M. Dómine, M. Cobo, 2020, Clinical and Translational Oncology.

Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer.

A. Carrato, C. García-Girón, R. Rosell, 2004, Clinical lung cancer.

Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database

N. Viñolas, M. Provencio, P. Garrido, 2017, Clinical and Translational Oncology.

SEOM clinical guidelines for the treatment of invasive bladder cancer

J. Carles, A. Font, R. Morales, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM)

J. Baselga, J. Albanell, R. Rosell, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07.

E. Felip, N. Viñolas, M. Provencio, 2016, Anticancer research.

MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC.

P. Garrido, F. Griesinger, É. Dansin, 2012, Lung cancer.

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.

E. Felip, F. de Marinis, L. Paz-Ares, 2015, JAMA oncology.

A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR).

L. Paz-Ares, B. Massuti, M. Provencio, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and Safety Results From a Phase II, Placebo‐Controlled Study of Onartuzumab Plus First‐Line Platinum‐Doublet Chemotherapy for Advanced Squamous Cell Non–Small‐Cell Lung Cancer

R. Govindan, F. Hirsch, D. Gandara, 2017, Clinical lung cancer.

Erlotinib customization based on epidermal growth factor receptor (EGFR) mutations in stage IV non-small-cell lung cancer (NSCLC) patients (p)

R. Rosell, M. Taron, M. Provencio, 2008 .

Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.

J. Riess, E. Felip, L. Paz-Ares, 2019, Clinical lung cancer.

Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib

B. Massuti, M. Lázaro, I. Oyagüez, 2020, Lung cancer management.

Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study

E. Felip, N. Viñolas, P. Garrido, 2020, BMC Psychology.

Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium.

H. Morgenstern, L. Kiemeney, H. Brenner, 2012, European journal of cancer.

Zoledronic acid in lung cancer with bone metastases: a review

J. Bosch-Barrera, N. Martínez, D. Isla, 2013, Expert review of anticancer therapy.

PD2-3-3: High correspondence between EGFR mutations in tissue and in circulating DNA form non-small-cell lung cancer (NSCLC) patients (p) with poor performance status (PS)

L. Paz-Ares, R. Rosell, M. Tarón, 2007 .

Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901.

R. Rosell, M. Sánchez-Ronco, B. Massuti, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.

M. Tsuboi, U. Dafni, R. Stahel, 2022, The Lancet. Oncology.

Diagnosis of Malnutrition According to GLIM Criteria Predicts Complications and 6-Month Survival in Cancer Outpatients

J. Lambea, J. Arbonés-Mainar, D. Isla, 2022, Biomedicines.

O-2 TWO second-line docetaxel dose-schedules in advanced non-small-cell lung cancer (NSCLC): A Spanish lung cancer group (SLCG) phase III trial

Ana María Jiménez, A. Carrato, R. Rosell, 2003 .

1222OA RANDOMIZED, OPEN-LABEL, PHASE III TRIAL OF AFATINIB (A) VS ERLOTINIB (E) AS SECOND-LINE TREATMENT OF PATIENTS (PTS) WITH ADVANCED SQUAMOUS CELL CARCINOMA (SCC) OF THE LUNG FOLLOWING FIRST-LINE PLATINUM-BASED CHEMOTHERAPY: LUX-LUNG 8 (LL8).

K. Syrigos, E. Felip, J. Soria, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

1303PDNivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ≥70 years and with poor performance status

J. Jassem, L. Paz-Ares, T. Ciuleanu, 2017 .

SEOM clinical guidelines for the treatment of anal cancer

J. Feliu, J. Maurel, D. Isla, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

How Could Antibiotics, Probiotics, and Corticoids Modify Microbiota and Its Influence in Cancer Immune Checkpoint Inhibitors: A Review

D. Isla, J. Pardo, E. M. Gálvez, 2021, Infection and immunity.

SEOM clinical guidelines for the treatment of oesophageal cancer

C. Pericay, A. Cervantes, D. Isla, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

ABEL trial: A phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited-stage small cell lung cancer (SCLC)—Final results.

R. Rosell, B. Massuti, A. Font, 2012 .

PD-1 is expressed in cytotoxic granules of NK cells and rapidly mobilized to the cell membrane following recognition of tumor cells

D. Isla, J. Pardo, A. Ramírez-Labrada, 2022, Oncoimmunology.

Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy: results of the NeoPrevent study

D. Isla, J. Castro, J. Manzano, 2006, Cancer Chemotherapy and Pharmacology.

Safety of bevacizumab-based therapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): MO19390 (SAiL)

N. Pavlakis, L. Crinò, N. Thatcher, 2008 .

Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance.

C. Escriu, P. Tomasini, K. Clark-Langone, 2020, NPJ precision oncology.

Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial.

A. Carrato, E. Felip, R. Rosell, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Cisplatin/gemcitabine (CG) vs cisplatin/gemcitabine/vinorelbine (CGV) vs sequential doublets of gemcitabine/vinorelbine followed by ifosfamide/vinorelbine (gv/iv) in advanced non-small cell lung cancer (NSCLC): final results of a Spanish lung cancer group phase III trial (GEPC/98-02)

R. Rosell, M. Provencio, C. Camps, 2001 .

A Subset of PD-1-Expressing CD56bright NK Cells Identifies Patients with Good Response to Immune Checkpoint Inhibitors in Lung Cancer

D. Isla, J. Pardo, A. Ramírez-Labrada, 2023, Cancers.

New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

E. Felip, L. Paz-Ares, P. Garrido, 2022, Clinical and Translational Oncology.

Prognostic Value of Serum S-100B in Malignant Melanoma

A. Tres, J. Mayordomo, R. Andrés, 2004, Tumori.

Prognostic Significance and Diagnostic Value of Protein S-100 and Tyrosinase in Patients With Malignant Melanoma

A. Tres, M. Ruiz-Echarri, J. Mayordomo, 2008, American journal of clinical oncology.

Sequence variants at the TERT-CLPTM1L locus associate with many cancer types

Paolo Vineis, Giuseppe Matullo, Kari Stefansson, 2009, Nature Genetics.

Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis

A. Navarro, M. Dómine, M. Cobo, 2022, Oncology and Therapy.

PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis

L. Paz-Ares, D. Rodríguez-Abreu, M. Cobo, 2021, Journal of clinical medicine.

Reflections on the Implementation of Low-Dose Computed Tomography Screening in Individuals at High Risk of Lung Cancer in Spain.

L. Paz-Ares, Marcelo Sánchez, P. Garrido, 2017, Archivos de bronconeumologia.

Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.

M. Taron, M. Sánchez-Ronco, J. Sánchez, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Epidermal Growth Factor Receptor Activation: How Exon 19 and 21 Mutations Changed Our Understanding of the Pathway

R. Rosell, M. Taron, N. Reguart, 2006, Clinical Cancer Research.

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial

E. Felip, A. Ardizzoni, Y. Min, 2021, EClinicalMedicine.

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers

L. Bubendorf, R. Stahel, S. Peters, 2018, Clinical Cancer Research.

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial

K. Syrigos, E. Felip, J. Soria, 2018, JAMA oncology.

[Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology].

N. Reguart, J. Ferreirós, M. Cobo, 2015, Radiologia.

From Tumor Mutational Burden to Blood T Cell Receptor: Looking for the Best Predictive Biomarker in Lung Cancer Treated with Immunotherapy

D. Isla, J. Pardo, E. M. Gálvez, 2020, Cancers.

Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

F. López-Ríos, E. Felip, L. Paz-Ares, 2015, Clinical and Translational Oncology.

Genome-wide significant association between a sequence variant at 15q15.2 and lung cancer risk.

D. Gudbjartsson, T. Thorgeirsson, L. Kiemeney, 2011, Cancer research.

MDR-1 C3435T Genetic Polymorphism and Tobacco-Related Lung Cancer

D. Isla, S. Bello, M. L. Bernal, 2003, Oncology.

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.

K. Syrigos, E. Felip, J. Soria, 2015, The Lancet. Oncology.

Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients

G. Bepler, R. Rosell, K. Danenberg, 2004, Clinical Cancer Research.

Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.

K. Syrigos, E. Felip, J. Soria, 2017, Lung cancer.

Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients.

R. Rosell, Jia Wei, M. Taron, 2010, Lung cancer.

Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8).

K. Syrigos, E. Felip, J. Soria, 2015 .

Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors

M. Provencio, R. García-Campelo, D. Isla, 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Intratumoral versus Circulating Lymphoid Cells as Predictive Biomarkers in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Is the Easiest Path the Best One?

D. Isla, J. Pardo, E. M. Gálvez, 2020, Cells.

Screening for epidermal growth factor receptor mutations in lung cancer.

Mariano Provencio, Miguel Angel Molina, Bartomeu Massuti, 2009, The New England journal of medicine.

Pharmacogenomics and gemcitabine.

R. Rosell, B. Massuti, C. Camps, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Applications of genomics in NSCLC.

G. Altavilla, R. Rosell, M. Taron, 2005, Lung cancer.

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

M. Provencio, I. Barneto, J. Valdivia, 2018, BMC Cancer.

Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer

Miguel Angel Molina, Bartomeu Massuti, Carlos Camps, 2010, Journal of Translational Medicine.

Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations

J. Mate, C. Sawyers, A. Ariza, 2011, Clinical Cancer Research.

Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain

D. Isla, M. López-Brea, D. Carcedo, 2023, Cost Effectiveness and Resource Allocation.

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.

L. Paz-Ares, M. Provencio, P. Garrido, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

The place of targeted therapies in the management of non-small cell bronchial carcinoma. Molecular markers as predictors of tumor response and survival in lung cancer.

R. Rosell, J. Ramírez, C. Camps, 2006, Revue des maladies respiratoires.

Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications.

B. Massuti, P. Garrido, D. Isla, 2015, Clinical lung cancer.

Inoperable stage III non-small cell lung cancer: Current treatment and role of vinorelbine.

M. Provencio, D. Isla, B. Cantos, 2011, Journal of thoracic disease.

Hepatocellular and biliary tract carcinomas: SEOM clinical guidelines

J. Feliu, J. Maurel, D. Isla, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.

E. Felip, L. Paz-Ares, M. Provencio, 2019, Lung cancer.

Sex differences in non-small cell lung cancer (NSCLC) patients (p) participating in Spanish Lung Cancer Group (SLCG) trials

R. Rosell, N. Viñolas, P. Garrido, 2007 .

Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP)

F. López-Ríos, E. Felip, L. Paz-Ares, 2012, Clinical and Translational Oncology.

Pharmacogenetics in lung cancer for the lay doctor

R. Rosell, M. Taron, B. Massuti, 2008, Targeted Oncology.

Comparing Cisplatin Plus Fluorouracil to Paclitaxel , Cisplatin , and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck Cancer

J. Carles, L. Paz-Ares, R. Hitt, 2006 .

Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.

J. Carles, L. Paz-Ares, R. Hitt, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.

A. Carrato, E. Felip, R. Rosell, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SEOM clinical guidelines for using molecular markers in clinical practice

V. Arrazubi, R. Pazo, D. Isla, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

GLIM vs ESPEN criteria for the diagnosis of early malnutrition in oncological outpatients.

J. Lambea, J. Arbonés-Mainar, D. Isla, 2021, Clinical nutrition.

Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection.

B. Massuti, M. Provencio, Fabio Franco, 2021, Lung cancer.

CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations.

J. Milanowski, E. Felip, J. V. van Meerbeeck, 2020, European journal of cancer.

Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study).

N. Viñolas, B. Massuti, M. Provencio, 2019, Lung cancer.

Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer.

A. Carrato, E. Felip, B. Massuti, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study.

S. Cedrés, N. Viñolas, M. Dómine, 2020, Clinical lung cancer.

Lung Cancer in Never-Smoking Women: A Sub-Analysis of the Spanish Female-Specific Database WORLD07

E. Felip, N. Viñolas, M. Provencio, 2017, Cancer investigation.

Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer

D. Isla, S. Grau, D. Rubio-Rodríguez, 2016, ClinicoEconomics and outcomes research : CEOR.

A consensus statement on the gender perspective in lung cancer

J. Borrás, F. López-Ríos, E. Felip, 2017, Clinical and Translational Oncology.

Lung cancer in women: an overview with special focus on Spanish women

E. Felip, N. Viñolas, P. Garrido, 2014, Clinical and Translational Oncology.

A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.

J. Bosch-Barrera, R. Rosell, N. Reguart, 2017, Lung cancer.

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.

R. Rosell, M. Taron, N. Reguart, 2014, Lung Cancer.

Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.

Antonio Nieto, Mariano Provencio, Bartomeu Massuti, 2012, Lung cancer.

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

E. Felip, L. Paz-Ares, M. Provencio, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance

A. Bergamaschi, F. Baehner, C. Escriu, 2020, npj Precision Oncology.

A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study

E. Felip, A. Insa, D. Isla, 2022, Clinical and Translational Oncology.

Thermal Liquid Biopsy (TLB): A Predictive Score Derived from Serum Thermograms as a Clinical Tool for Screening Lung Cancer Patients

O. Abián, A. Velázquez‐Campoy, Á. Lanas, 2019, Cancers.

Desmoplastic small round cell tumor of the abdomen

S. Cajal, A. Tres, M. Ruiz-Echarri, 2006 .

SEOM guidelines for the management of non-small-cell lung cancer (NSCLC)

E. Felip, L. Paz-Ares, M. Provencio, 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.

R. Stahel, R. Rosell, M. Taron, 2011, Lung cancer.

Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer.

R. Rosell, M. Taron, M. Sánchez-Ronco, 2004, Clinical lung cancer.

Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

C. García-Girón, J. Bosch-Barrera, E. Esteban, 2020, BMC Cancer.

Prognostic value of quantitative immune alterations in melanoma patients

A. Tres, J. Mayordomo, J. Godino, 2006 .

Longitudinal Evolution of Cognitive Function in Colorectal and Breast Cancer Survivors Treated with (Neo)Adjuvant Chemotherapy.

R. Andrés, L. Murillo, D. Isla, 2021 .

SEOM clinical guidelines for the treatment of pancreatic cancer

M. Hidalgo, J. Tabernero, D. Isla, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Platinum resistance related to a functional NER pathway.

R. Rosell, M. Taron, P. Méndez, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non–Small‐Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery

R. Rosell, M. Santarpia, J. Ramírez, 2017, Clinical lung cancer.

Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM)

E. Felip, P. Garrido, D. Isla, 2021, ESMO open.

SEOM clinical guidelines for hereditary cancer

G. Llort, J. Brunet, D. Isla, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

SEOM clinical guidelines for diagnosis and treatment of testicular seminoma (2010)

J. Aparicio, D. Isla, J. Sastre, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

A Paradigm Shift for Resectable Non-Small Cell Lung Cancer.

D. Isla, M. Majem, 2022, Archivos de bronconeumologia.

EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use.

M. Tsuboi, U. Dafni, R. Stahel, 2022, Journal of Clinical Oncology.

VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study

U. Dafni, R. Stahel, M. Mauer, 2022, Annals of Oncology.

930MO PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: Subgroup analysis of PEARLS/KEYNOTE-091

U. Dafni, R. Stahel, M. Mauer, 2022, Annals of Oncology.

Final development and validation of the BOMET-QoL questionnaire for assessing quality of life in patients with malignant bone disease due to neoplasia

X. Badia, M. Pastor, B. Massuti, 2007 .

Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: mature results of the Spanish Lung Cancer Group 0008 study.

R. Rosell, B. Massuti, J. Zamora, 2013, Lung cancer.

SEOM guidelines: non-seminomatous germ cell cancer (NSGCC)

P. Maroto, D. Isla, J. Sastre, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts

C. Henschke, L. Crinò, F. Barlesi, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.

A. Tres, J. Mayordomo, R. Andrés, 2005, Clinical breast cancer.

Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study.

R. Rosell, A. Font, R. Lecumberri, 2013, Thrombosis research.

Lung cancer in Spanish women: The WORLD07 project

Mariano Provencio, E. Felip, N. Viñolas, 2018, European journal of cancer care.

P3.01-043 Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung

E. Felip, J. Soria, A. Ardizzoni, 2017 .

LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

E. Felip, J. Bosch-Barrera, J. Palacios, 2021, Cancer medicine.

Cisplatin/gemcitabine (CG) vs cisplatin/gemcitabine/vinorelbine (CGV) vs sequential doublets of gemcitabine/vinorelbine followed by ifosfamide/vinorelbine (GV/IV) in advanced non-small cell lung cancer. Interim analysis of a Spanish Lung Cancer Group (SLCG) phase III trial

R. Rosell, M. Provencio, C. Camps, 2000 .

ERCC1 mRNA-based randomized phase III trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage IV non-small-cell lung cancer (NSCLC) patients (p)

E. Felip, R. Rosell, N. Viñolas, 2005 .

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy

Edward S. Kim, M. Socinski, C. Gridelli, 2017, Lung Cancer.

Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC).

L. Bubendorf, R. Stahel, S. Peters, 2017 .

Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus

E. Felip, L. Paz-Ares, P. Garrido, 2019, Clinical and Translational Oncology.

Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancer.

A. Carrato, R. Rosell, R. Sirera, 2009, Lung cancer.

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.

A Vergnenegre, X. Chen, X. Qian, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts.

C. Henschke, L. Crinò, F. Barlesi, 2012 .

Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology

J. Ferreirós, M. Cobo, D. Isla, 2014, Clinical and Translational Oncology.

Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC)

J. Mayordomo, F. Rivera, D. Isla, 2008, Cancer Chemotherapy and Pharmacology.

The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium.

Michael A. Rodriguez, A. Ruano-Raviña, E. Felip, 2023, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO).

Abidemi K. Adeniji, J. Riess, E. Felip, 2022, Lung cancer.

Open, phase II randomized trial of gefitinib alone versus olaparib (AZD2281) plus gefitinib in advanced non-small cell lung cancer (NSCLC) patients (P) with epidermal growth factor receptor (EGFR) mutations: Spanish Lung Cancer Group trial (NCT=1513174/GECP-GOAL).

R. Rosell, N. Reguart, B. Massuti, 2014 .

Identification of AEG-1 and BARD1 as predictors of erlotinib outcome in EGFR-mutant non-small cell lung cancer (NSCLC) by NanoString multiple target profiling.

M. Taron, M. Santarpia, S. Benlloch, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions

J. Aparicio, F. Rivera, Montserrat Muñoz, 2016, Clinical and Translational Oncology.

1010P Assessment of early resistance mechanisms to first-line osimertinib in EGFR-mutant NSCLC using spatial transcriptomics

J. Zugazagoitia, D. Isla, J. M. Sánchez Torres, 2022, Annals of Oncology.

Interim analysis of the Spanish Lung Cancer Group (SLCG) BRCA1-RAP80 Expression Customization (BREC) randomized phase III trial of customized therapy in advanced non-small cell lung cancer (NSCLC) patients (p) (NCT00617656/GECP-BREC).

R. Rosell, M. Sánchez-Ronco, M. Provencio, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.